A board-certified radiation oncologist, Dr. David Raben joins Bicara with more than 25 years of biopharma and academic translational oncology experience, having most recently served as vice president of global product development and product general manager, of oncology, at Amgen. At Amgen, his work centered on driving the anti-DLL3 program in neuroendocrine cancers. Before that, David served as vice president and franchise leader, of clinical development oncology, at Genentech, focusing on precision medicine and immunotherapy trials in head and neck, thoracic, skin, and rare cancers, in both late-stage and locally advanced settings.
David has spent more than 20 years as a professor and an associate member of the University of Colorado Cancer Center, where his main areas of focus have been evaluating and combining novel biologic therapies in the laboratory and clinical trials for patients with locally advanced cancers of the head and neck and lung. His extensive clinical expertise in the management of head, neck, and thoracic cancers also extends to genitourinary cancers, along with translational experience in areas such as EGFR signaling, DNA damage repair, TGFb, and checkpoint inhibition.
Nationally, David served on the NRG Oncology Head and Neck Cancer (HNC) steering committee for over 15 years and established and led the Radiation Developmental Therapeutics Committee at the NRG. He remains an active member of the American Head and Neck Society, IASLC, ESMO, AACR, and ASTRO. Dr. Raben has authored over 180 publications, 13 book chapters, and his research has been published in high-impact journals including the New England Journal of Medicine, Clinical Cancer Research, Nature Medicine, and Nature Biology Communications.
David holds a Bachelor of Arts degree from Duke University and earned his MD from Wake Forest University. He completed his residency training in Radiation Oncology at the Johns Hopkins Hospital.
What is David Raben's net worth?
The estimated net worth of David Raben is at least $1.15 million as of March 4th, 2026. Raben owns 55,286 shares of Bicara Therapeutics stock worth more than $1,152,713 as of April 6th. This net worth evaluation does not reflect any other assets that Raben may own. Learn More about David Raben's net worth.
How do I contact David Raben?
Has David Raben been buying or selling shares of Bicara Therapeutics?
David Raben has not been actively trading shares of Bicara Therapeutics within the last three months. Most recently, David Raben sold 16,300 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $18.52, for a transaction totalling $301,876.00. Following the completion of the sale, the insider now directly owns 55,286 shares of the company's stock, valued at $1,023,896.72. Learn More on David Raben's trading history.
Who are Bicara Therapeutics' active insiders?
Are insiders buying or selling shares of Bicara Therapeutics?
In the last year, insiders at the sold shares 33 times. They sold a total of 374,566 shares worth more than $6,946,222.67. The most recent insider tranaction occured on March, 23rd when CFO Ivan Hyep sold 9,200 shares worth more than $170,384.00. Insiders at Bicara Therapeutics own 15.5% of the company.
Learn More about insider trades at Bicara Therapeutics. Information on this page was last updated on 3/23/2026.
